🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

2,762 results for “CTI” Clear

  1. Placebo in combination with Cytarabine Injection

    Moleculin Biotech

    Acute Myeloid Leukaemia (AML)

    phase 3 small molecule active

    1 trial

  2. Placebo injection, 0.8 ml is a sterile, preservative-free, parenteral solution of sodium chloride and riboflavin in water for injection (wfi) intended for subcutaneous injection, ISIS 678354

    IONIS PHARMACEUTICALS INC

    Severe Hypertriglyceridemia.

    phase 3 small molecule active

    1 trial

  3. Placebo injections

    Centocor B.V.

    Rheumatoid Arthritis

    phase 3 small molecule completed

    1 trial

  4. Placebo intramuscular injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Spontaneous Uriticaria

    phase 3 small molecule active

    1 trial

  5. Placebo is 0.9% (w/v) NaCl for injection and is to be provided by sites., IVX-A12

    AstraZeneca AB

    Respiratory Syncytial Virus and Human Metapneumovirus

    phase 3 small molecule active

    1 trial

  6. Placebo is a sterile solution in a single use prefilled syringe (PFS) intended for subcutaneous administration., Skyrizi 150 mg solution for injection in pre-filled syringe, Sonelokimab, Sonelokimab

    MoonLake Immunotherapeutics

    psoriatic arthritis

    phase 3 small molecule active

    1 trial

  7. Placebo is identical to the active NMRA-335140 but without the active drug substance to maintain study blinding., NMRA-335140

    Neumora Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    1 trial

  8. Placebo is identical to the active drugs but without the active drug substance to maintain study blinding. Niraparib placebo tablets, Dostarlimab placebo infusion bags, JEMPERLI 500 mg concentrate for solution for infusion

    TESARO Bio Netherlands B.V.

    Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer

    phase 3 small molecule active

    1 trial

  9. Placebo is solution for injection (150 mg/ml) contained in vials equal to those of Canakinumab and appears identical to the Test product. Placebo is provided by Novartis pharma., Ilaris 150 mg/ml solution for injection

    Istituto Gentili S.r.l.

    PAPA syndrome

    phase 3 small molecule active

    1 trial

  10. Placebo matching < Staccato® alprazolam > and without active substance, alprazolam

    Lacuna Pharma Pty Ltd

    Stereotypical prolonged seizure

    phase 3 small molecule active

    1 trial

  11. Placebo matching IMP., Vyvgart 1 000 mg solution for injection in pre-filled syringe

    argenx

    Primary Sjögren’s Disease

    phase 3 small molecule active

    1 trial

  12. Placebo matching Ozanimod hard-gelatin capsules, Ozanimod, Ozanimod

    Celgene Europe Limited

    Moderately to Severely Active Crohn's Disease

    phase 3 small molecule active

    1 trial

  13. Placebo matching test and comparator. 0.9% sodium chloride solution for injection (unauthorized), ustekinumab, Placebo matching test and comparator. 0.9% sodium chloride solution for injection (authorized - MA number: 6697366.00.00), bimekizumab

    Lacuna Pharma Pty Ltd

    Moderate to Severe Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  14. Placebo of BELAPECTIN, BELAPECTIN

    GALECTIN THERAPEUTICS INC

    Esophageal Varices in NASH Cirrhosis

    phase 3 small molecule active

    1 trial

  15. Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg

    Amneal Pharma Europe Ltd

    Uncomplicated Urinary Tract Infections

    phase 3 small molecule completed

    1 trial

  16. Placebo of XEOMIN 100UY, powder for injection, XEOMIN 100 unités, poudre pour solution injectable

    Pari Pharma GmbH

    incisional hernia

    phase 3 small molecule active

    1 trial

  17. Placebo of ZIMINO (glucose 5%), ZIMINO 2,5 mg/ml, solution à diluer pour perfusion

    Pari Pharma GmbH

    Patients referred for an isolated or a combined surgical correction of functional moderate to severe tricuspid regurgitation

    phase 3 small molecule active

    1 trial

  18. Placebo tablets without active pharmaceutical ingredient closely resembling the imp, Hetrombopag Olamine

    Lacuna Pharma Pty Ltd

    Chemotherapy induced thrombocytopenia

    phase 3 small molecule active

    1 trial

  19. Placebo to AIN457 150 mg/ 1 mL Solution for injection in pre-filled syringe. This placebo is an additional/ alternative placebo to placebo to Xolair® (Omalizumab) to ensure continuous supply in the clinical trial. For more details please refer to Note to Assessor located in the “Placebo to AIN457” product shell., OMALIZUMAB , -, Placebo to Xolair® (Omalizumab) 150 mg/ml solution for injection in pre-filled syringe, LOU064, Placebo to Remibrutinib (LOU064) 25 mg film-coated tablet, -

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  20. Placebo to AIN457 300 mg/2 mL Solution for injection in pre-filled syringe, Cosentyx 300 mg solution for injection in pre-filled syringe

    Novartis Pharmaceuticals

    Giant Cell Arteritis

    phase 3 small molecule active

    1 trial

  21. Placebo to AIN457 300mg/2mL Solution for injection in pre-filled syringe, SECUKINUMAB

    Novartis Pharmaceuticals

    Hidradenitis suppurativa

    phase 3 small molecule active

    1 trial

  22. Placebo to ARGX-113 solution for injection, ARGX-113

    argenx

    Active Idiopathic Inflammatory Myopathy (IIM)

    phase 3 small molecule active

    1 trial

  23. Placebo to Guselkumab Solution for injection in pre-filled syringe 100 mg/ml., Guselkumab - solution for injection in pre-filled syringe - 100 mg/mL

    Janssen-Cilag International N.V.

    Psoriatic arthritis (PsA)

    phase 3 small molecule active

    1 trial

  24. Placebo to Match Tinlarebant (LBS-008). Placebo tablets will be prepared similarly with microcrystalline cellulose used in place of the active drug substance. The placebo tablet is identical in size, appearance, and other physical properties to the LBS-008 tablet., LBS-008

    ELITE PHARMACEUTICALS INC /NV/

    Geographic Atrophy

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources